<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180153</url>
  </required_header>
  <id_info>
    <org_study_id>ChinaBJCH_SOX_BTC</org_study_id>
    <nct_id>NCT01180153</nct_id>
  </id_info>
  <brief_title>Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)</brief_title>
  <official_title>An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with
      unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To list in cases with unresectable, metastatic or locally advanced biliary tract or ampullary
      adenocarcinoma that have not been treated before,confirm the efficacy and safety of combined
      S-1/L-OHP regimen for the biliary tract or ampullary carcinoma, providing evidence-based
      proof for the future treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>to evaluate objective response rate (ORR) of SOX regimen to BTC (Ampullary Adenocarcinoma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>to evaluate survival data of overall survival (OS),Progression free Survival(PFS), safety outcome of SOX regimen to BTC (Ampullary Adenocarcinoma)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>SOX: advanced BTC or ampullary carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 oxaliplatin</intervention_name>
    <description>S-1 (20mg, 25mg); L-OHP (50 mg)</description>
    <arm_group_label>SOX: advanced BTC or ampullary carcinoma</arm_group_label>
    <other_name>S-1 (20mg, 25mg); L-OHP (50 mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent has been signed by the subject itself;

          2. Aged over 18;

          3. With a definite pathological or cytological diagnosis of adenocarcinoma;

          4. No pre-treatment (including radiotherapy, chemotherapy, immunotherapy, etc.). For
             recurrent cases, if the subjects have received adjuvant chemotherapy without S-1 or
             L-OHP after surgery and the time to the end date of adjuvant chemotherapy is over 6
             months, they can also be enrolled;

          5. Enhanced helical CT or MRI scanning shows a target lesion over 1cm within 14 days
             before enrollment

          6. Within 7 days before enrollment, baseline blood routine and biochemical indicators
             meet the following criteria:

               -  Hemoglobin ≥ 90g/L,

               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L,

               -  Platelets ≥ 100×109/L，

               -  Serum total bilirubin &lt; 1.5 times of the upper normal limit,

               -  Serum creatinine &lt; upper limit of normal,

               -  Serum albumin ≥ 30 g/L;

          7. Can receive oral administration;

          8. Karnofsky(KPS) score ≥ 70 points;

          9. Expected survival time is more than 90 days;

         10. Women of childbearing age must receive urine or blood pregnancy test within 7 days
             before randomization and the results are negative;

         11. Male and female patients of appropriate reproductive age are willing to use reliable
             contraception methods for contraception in the process of study till 30 days after
             drug withdrawal.

        Exclusion Criteria:

          1. Patients with a severe drug allergy history (including mildly allergic to L-OHP, 5-FU,
             FT207, 5-HT3 receptor antagonist);

          2. Patients who participated or are participating in other clinical trials within 4 weeks
             before enrollment;

          3. Patients who have received blood transfusion, blood products and hematopoietic factor
             preparations such as G-CSF within 15 days before enrollment;

          4. Patients who have undergone a surgery within 15 days before enrollment, and its
             effects have not been eliminated;

          5. Patients with diarrhea;

          6. Patients with a complication of active infection (infection causes a fever above 38
             ℃);

          7. Patients accompanied by dysphagia, complete or incomplete gastrointestinal
             obstruction, active gastrointestinal bleeding and perforation, etc. that cause
             difficulty in taking S-1 orally;

          8. Patients with severe liver disease (e.g. active hepatitis, cirrhosis, etc.), renal
             insufficiency, severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe
             emphysema, etc.), or uncontrollable diabetes, hypertension and other chronic systemic
             diseases;

          9. Patients who have received long-term systemic steroid therapy (Note: short-term users
             with steroid withdrawal &gt; 2 weeks can be selected);

         10. Patients with brain metastases or suspected of brain metastases;

         11. Patients with peripheral nervous system disorder or a history of significant mental
             disorder and central nervous system disorder;

         12. Heart disease of significant clinical symptoms, e.g. congestive heart failure,
             coronary heart disease with significant symptoms, arrhythmia and hypertension that are
             difficult to be controlled by drugs, or with an episode of myocardial infarction
             within 6 months, or cardiac insufficiency;

         13. Patients with pleural effusion, ascites, or pericardial effusion that needs drainage;

         14. Pregnant or breast-feeding women, or male and female patients of appropriate
             reproductive age who refuse to take contraceptive measures;

         15. Patients who have suffered from other malignancies within 5 years, except basal cell
             carcinoma and carcinoma in situ of uterine cervix that have already been cured;

         16. Patients without legal capability, or who can not continue the study due to medical or
             ethical reasons;

         17. Patients who are determined not suitable to participate in this clinical trial by the
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Li, Doctor</last_name>
    <phone>010-88121122</phone>
    <phone_ext>321</phone_ext>
    <email>xiaotong10241@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chin Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Li, Doctor</last_name>
      <phone>010-88121122</phone>
      <phone_ext>321</phone_ext>
      <email>xiaotong10241@sin.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Shen</last_name>
      <phone>010-59714220</phone>
      <email>ian97@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lin Shen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>August 11, 2010</last_update_submitted>
  <last_update_submitted_qc>August 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lin Shen</name_title>
    <organization>Beijing Cancer Hospital</organization>
  </responsible_party>
  <keyword>40 S-1/L-OHP</keyword>
  <keyword>biliary tract</keyword>
  <keyword>ampullary carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

